We are live on ! Find out more
ACA

Avoro Capital Advisors Portfolio holdings

AUM $10.2B
1-Year Est. Return 149.19%
This Fund
S&P 500
This Quarter Est. Return
+7.99%
1 Year Est. Return
+149.19%
3 Year Est. Return
+425.03%
5 Year Est. Return
+775.33%
10 Year Est. Return
+45,729.2%
AUM
$6.86B
AUM Growth
-$650M
Cap. Flow
-$889M
Cap. Flow %
-12.96%
Top 10 Hldgs %
69.62%
Holding
42
New
1
Increased
10
Reduced
8
Closed
6

Top Buys

Rank Stock Value
1
ASND icon
Ascendis Pharma A/S
ASND
+$107M
2
PCVX icon
Vaxcyte
PCVX
+$54.1M
3
KRYS icon
Krystal Biotech
KRYS
+$36.5M
4
KYMR icon
Kymera Therapeutics
KYMR
+$27M
5
DYN icon
Dyne Therapeutics
DYN
+$21.3M

Top Sells

Rank Stock Value
1
CERE
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
+$308M
2
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$281M
3
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$211M
4
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$97.2M
5
IOVA icon
Iovance Biotherapeutics
IOVA
+$70.7M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RARE icon
26
Ultragenyx Pharmaceutical
RARE
$2.55B
$46.1M 0.67%
830,000
– –
AUTL
27
Autolus Therapeutics
AUTL
$532M
$44.8M 0.65%
12,345,678
– –
IOVA icon
28
Iovance Biotherapeutics
IOVA
$2.77B
$39.8M 0.58%
4,240,000
-7,460,000
-64% -$70.7M
TSHA icon
29
Taysha Gene Therapies
TSHA
$1.82B
$37.5M 0.55%
18,650,000
– –
GLUE icon
30
Monte Rosa Therapeutics
GLUE
$1.33B
$30.7M 0.45%
5,790,236
+1,255,236
+28% +$6.34M
CGON icon
31
CG Oncology
CGON
$6.6B
$26.4M 0.39%
700,000
– –
DYN icon
32
Dyne Therapeutics
DYN
$4.83B
$23.3M 0.34%
650,000
+534,249
+462% +$21.3M
SYRE icon
33
Spyre Therapeutics
SYRE
$9.12B
$17.6M 0.26%
598,600
-1,240,538
-67% -$34.5M
WHWK
34
Whitehawk Therapeutics
WHWK
$232M
$5.87M 0.09%
2,849,402
– –
NGNE icon
35
Neurogene
NGNE
$710M
$924K 0.01%
22,029
– –
INSM icon
36
PUT
Insmed
INSM
$28.9B
$125K ﹤0.01%
+50,000
New +$3.69M
ADVM
37
DELISTED
Adverum Biotechnologies
ADVM
– –
-416,666
Closed -$2.86M
ALNY icon
38
Alnylam Pharmaceuticals
ALNY
$28.9B
– –
-400,000
Closed -$97.2M
BCYC
39
Bicycle Therapeutics
BCYC
$278M
– –
-700,000
Closed -$14.2M
VRCA icon
40
Verrica Pharmaceuticals
VRCA
$92.1M
– –
-400,000
Closed -$29.2M
XBI icon
41
State Street SPDR S&P Biotech ETF
XBI
$10.1B
– –
-3,035,000
Closed -$281M
CERE
42
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
– –
-7,539,547
Closed -$308M
1
2

Similar funds

IIM
INTECH Investment Management West Palm Beach, Florida $10.2B AUM 28.14% 1-Year Est. Return
GI
GAMCO Investors Greenwich, Connecticut $10.2B AUM 30.27% 1-Year Est. Return
VPIM
Vanguard Personalized Indexing Management Oakland, California $10.2B AUM 34.45% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

Avoro Capital Advisors's Q3 2024 Portfolio in Review

As of Q3 2024, Avoro Capital Advisors held 42 positions worth $6.86B, down 8.7% from $7.51B the previous quarter. Its ten largest holdings account for 70% of the portfolio.

Avoro Capital Advisors withdrew a net $889M in Q3 2024, closing 6 positions and reducing 8 holdings. Its most notable exit was Cerevel Therapeutics Holdings, Inc. Common Stock, an estimated $308M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 96% a quarter earlier.

Against the trend, Avoro Capital Advisors added an estimated $107M to Ascendis Pharma A/S.

  • Avoro Capital Advisors added most to Ascendis Pharma A/S in Q3 2024, an estimated $107M increase.
  • Avoro Capital Advisors's biggest Q3 2024 reduction was BioMarin Pharmaceuticals, cutting an estimated $211M.
  • Avoro Capital Advisors fully exited Cerevel Therapeutics Holdings, Inc. Common Stock in Q3 2024, selling an estimated $308M.
  • Avoro Capital Advisors's ten largest holdings make up 70% of its $6.86B portfolio in Q3 2024.
  • Avoro Capital Advisors opened 1 new position and closed 6 in Q3 2024.
  • Avoro Capital Advisors's portfolio value fell 8.7% quarter-over-quarter to $6.86B.

Based on Avoro Capital Advisors's 13F filing for Q3 2024, filed 14 Nov 2024.